AI Prospecting for IQVIA Holdings

IQVIA Holdings Inc. reported strong fourth-quarter and full-year 2024 results, with revenue growth of 3.0% at constant currency and Adjusted Diluted Earnings per Share up 9.1% year-over-year. The company reaffirmed its 2025 guidance, expecting 4-7% revenue growth and Adjusted EBITDA margin expansion[3][5]. IQVIA also announced a strategic collaboration with NVIDIA to enhance its Healthcare-grade AI™, integrating NVIDIA's AI technologies to transform life science processes and improve patient outcomes[4].

IQVIA Holdings Inc. saw a significant surge in trading volume on April 9, 2025, with $922 million in shares exchanged, a 129.98% increase from the previous day, and the stock price rose by 8.67%[3]. IQVIA's recent report, "Global Trends in R&D 2025," highlighted that R&D funding reached a 10-year high of $102 billion in 2024, with 5,318 clinical trial starts and 65 novel active substances launched globally, despite geopolitical and economic challenges[2]. Mizuho reduced IQVIA's price target from $242.00 to $210.00 while maintaining an "outperform" rating, and other analysts have also adjusted their price targets, with a consensus rating of "Moderate Buy" and a target price of $241.50[1][4].

IQVIA's "Global Trends in R&D 2025" report shows R&D funding hit a 10-year high of $102 billion in 2024, with 5,318 clinical trial starts and 65 new drug launches, despite geopolitical and economic challenges. Mizuho lowered IQVIA's price target to $210.00, maintaining an "outperform" rating, with a consensus rating of "Moderate Buy" and a target price of $241.50[2][1][3].